GlassScriptPhysician profile
Fredric E Weiss
NPI 1336354059
$2,564.95
in general payments reported to CMS, 2019-2025
22 companies · $16.35 in 2025
The $16.35 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $65.40 · 2023: $1,281 · 2024: $1,202 · 2025: $16.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,425 · Education: $75.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,424.51 |
| Education | $75.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $327.14 | 2023-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $293.11 | 2023-2024 | Entyvio |
| Janssen Biotech, INC. | $292.74 | 2022-2024 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $192.52 | 2023-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $165.96 | 2023-2024 | Dificid |
| Celltrion USA INC. | $151.04 | 2024 | Vegzelma, Zymfentra |
| Ferring Pharmaceuticals INC. | $125.80 | 2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $122.99 | 2024 | Voquezna |
| Qol Medical, LLC | $105.54 | 2023-2024 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $105.53 | 2023 | Dupixent |
| Redhill Biopharma INC. | $102.43 | 2023-2024 | Talicia |
| Fresenius Kabi USA, LLC | $90.15 | 2023 | Idacio |
| Celgene Corporation | $66.47 | 2023 | Zeposia |
| Genzyme Corporation | $62.47 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.75 | 2023 | Cyltezo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $59.34 | 2023-2024 | Omvoh |
| Gilead Sciences, INC. | $56.62 | 2024 | |
| Intercept Pharmaceuticals, INC. | $51.07 | 2022-2024 | |
| Lucid Diagnostics INC. | $49.36 | 2023 | |
| Organon LLC | $31.90 | 2024 | |
| Aimmune Therapeutics, INC. | $28.21 | 2024 | |
| Pfizer INC. | $22.81 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fredric Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.